Mesenchymal Stem Cell Features of Ewing Tumors  by Tirode, Franck et al.
Cancer Cell
ArticleMesenchymalStemCell FeaturesofEwingTumors
Franck Tirode,1,2 Karine Laud-Duval,1,2 Alexandre Prieur,1,2 Bruno Delorme,3,4 Pierre Charbord,3,4
and Olivier Delattre1,2,*
1 Institut Curie, 26 rue d’Ulm, 75248 Paris cedex 05, France
2 INSERM, U830, Unite´ de Ge´ne´tique et Biologie des Cancers, 75248 Paris cedex 05, France
3 INSERM, Equipe ESPRIT EA3855, Microenvironnement de l’He´matopoie`se et Cellules Souches, 37032 Tours cedex 1, France
4 Universite´ de Tours, Faculte´ de Me´decine, 10 Boulevard Tonnelle, 37032 Tours cedex 1, France
*Correspondence: olivier.delattre@curie.fr
DOI 10.1016/j.ccr.2007.02.027
SUMMARY
The cellular origin of Ewing tumor (ET), a tumor of bone or soft tissues characterized by specific fu-
sions between EWS and ETS genes, is highly debated. Through gene expression analysis comparing
ETs with a variety of normal tissues, we show that the profiles of different EWS-FLI1-silenced Ewing
cell lines converge toward that of mesenchymal stem cells (MSC). Moreover, upon EWS-FLI1 silenc-
ing, two different Ewing cell lines can differentiate along the adipogenic lineage when incubated in
appropriate differentiation cocktails. In addition, Ewing cells can also differentiate along the osteo-
genic lineage upon long-term inhibition of EWS-FLI1. These in silico and experimental data strongly
suggest that the inhibition of EWS-FLI1may allow Ewing cells to recover the phenotype of their MSC
progenitor.INTRODUCTION
Ewing tumor (ET), the second most frequent bone tumor in
adolescents and young adults, harbors characteristic
translocations which fuse the 50 portion of the EWS gene
with the 30 region, encoding DNA binding domain, of one
of five ETS family genes (Arvand and Denny, 2001; Jan-
knecht, 2005). The specificity of these translocations for
ET has now been extensively documented. The most fre-
quent fusion occurs with the FLI1 gene as a consequence
of the t(11;22)(q24;q12) translocation (Delattre et al.,
1992). The resulting EWS-FLI1 chimeric protein behaves
as an aberrant transcription regulator that is thought to
induce transformation through induction or repression of
specific target genes. Accordingly, a number of genes
controlling cell growth, signal transduction, or differentia-
tion have been shown to be regulated by EWS-FLI1
(reviewed in Janknecht, 2005).
Histologically, ET appears as uniformly undifferentiated
small round cells containing a vesicular nuclei and a smallcytoplasm within a sparse intercellular stroma. These
characteristics are poorly indicative of the cell lineage
that gives rise to ET. Since the initial proposal of an endo-
thelial origin by James Ewing in 1921 (Ewing, 1921), the is-
sue of the ET progenitor is highly debated. A neural crest
origin is hypothesized by the observation that EWS-ETS
fusions characterize a spectrum of tumors with undifferen-
tiated ETs at one end and differentiated peripheral primi-
tive neuroectodermal tumors, expressing various neural
markers, at the other end. This hypothesis is further
strengthened by the observation that ET-derived cell lines
grown in vitro can undergo neural differentiation upon
treatment with various differentiation-inducing agents
(Cavazzana et al., 1987; Noguera et al., 1994). A recent
study suggests that EWS-FLI1 expression itself may be
responsible, at least in part, for the observed primitive
neuroectodermal phenotype of ET through the regulation
of neural-specific genes (Hu-Lieskovan et al., 2005). This
study indicates that the ultimate phenotype of ET might
be determined not only by the cell lineage from which itSIGNIFICANCE
The precise knowledge of the normal counterpart of cancer cells is dramatically lacking for Ewing sarcoma, one of
the most frequent primary bone tumors. Since its initial description more than 80 years ago, endothelial, epithelial,
neural, and mesenchymal origins have been hypothesized. We have developed original cell models to regulate
EWS-FLI1 expression. In silico analyses and in vitro differentiation experiments provide strong evidence that Ew-
ing tumors originate from a mesenchymal precursor that may have both connective and vascular differentiation
potentials. This origin helps clarify the issue of the predominant localization of ET in bone or soft tissue, two tissues
that constitute major sources of MSC.Cancer Cell 11, 421–429, May 2007 ª2007 Elsevier Inc. 421
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Mesenchymal Origin of Ewing Sarcomaderives but also by intrinsic effects of EWS-FLI1. EWS-
FLI1 has also been shown to inhibit neural differentiation
of neuroblastoma cells, therefore leading to the proposal
that EWS-FLI1 may shift the sympathetic differentiation
program of neuroblastoma to the parasympathetic one
of ET (Rorie et al., 2004).
Other experiments indicate that EWS-FLI1 inhibits mes-
enchymal differentiation. In particular, enforced expres-
sion of EWS-FLI1 inhibits adipogenic and osteogenic
differentiation in murine marrow stromal cells (Torchia
et al., 2003). It also impairs myogenic differentiation in
C2C12 myoblasts (Eliazer et al., 2003). The hypothesis
of a mesenchymal origin of ET is further supported by
two recent reports indicating that EWS-FLI1 can transform
primary bone marrow stromal cells and induce the forma-
tion of tumors resembling Ewing sarcomas in SCID mice
(Castillero-Trejo et al., 2005; Riggi et al., 2005). This indi-
cates that, unlike other cell types, which cannot be trans-
formed by EWS-FLI1 alone and necessitate additional
events, mesenchymal stem cells display permissiveness
for EWS-FLI1-mediated cell transformation and may
therefore constitute an appropriate background for ET
development.
Finally, together with the observation of occasional
cytokeratin staining, the study of tight-junction structural
proteins has suggested that ETs exhibit partial epithelial
differentiation (Schuetz et al., 2005).
Presently, all attempts to identify the ET cell of origin
have relied on the overexpression of EWS-FLI1 in various
heterologous backgrounds. In this study, we have tested
the hypothesis that Ewing cells, inhibited for EWS-FLI1
by a specific small hairpin RNA (shRNA), may recover
characteristics of their primary origin and responsiveness
to differentiation programs.
RESULTS
Convergence of EWS-FLI1-Silenced Ewing Cells
toward Mesenchymal Stem Cells In Silico
To gain insight into the origin of Ewing tumors (ET), we
compared the expression profile of 27 ETs with that of
various normal human tissues (Su et al., 2004), human
mesenchymal stem cells (MSCs) (Boquest et al., 2005)
and freshly prepared bonemarrow stromal cells (BMSCs).
This data set hence contained different tissues from neural
(central or peripheral), epithelial, hematopoietic, or mes-
enchymal origins. Duplicate data, obtained with three
Ewing cell lines silenced for EWS-FLI1 expression by
RNA interference, were also included in this in silico anal-
ysis. These silencing experiments were initially performed
with an EWS-FLI1-specific siRNA for the A673 cell line
which can be efficiently transfected (Prieur et al. 2004).
Given the low efficiency of such transfection in other cell
lines, we developed lentiviral vectors to express a shRNA
corresponding to the junction between EWS and FLI1
genes. This lentivirus was used to infect EW24 and SK-
N-MC cells. In addition, data recently published for EWS-
FLI1-silenced A673 cells (Smith et al., 2006) were also
included in this analysis (a complete description of the422 Cancer Cell 11, 421–429, May 2007 ª2007 Elsevier Inc.whole data set is provided in Table S1 in the Supplemental
Data available with this article online). All experiments,
performed on Affymetrix HG-U133A chips, were simulta-
neously normalized using gcrma. Hierarchical clustering
and principal component analyses (PCA) using all probe
sets showed that ETs formed a distinct group that also in-
cluded EWS-FLI1-silenced (efRNAi) and control (ctrlRNAi)
samples. This indicated that ET form a homogeneous
group not evidently related to any normal tissue (Fig-
ure 1A). Based on the hypothesis that EWS-FLI1 may
modulate differentiation genes, we performed a new
PCA analysis with genes strongly and significantly modu-
lated by EWS-FLI1 as identified by SAM analysis compar-
ing efRNAi and ctrlRNAi samples. As shown in Figure 1B,
ETs were still clustered with ctrlRNAi apart from other
tissues. In contrast, efRNAi samples shifted away from
the ET cluster to join the mesenchymal group containing
undifferentiated BMSCs or MSCs but also the more differ-
entiated adipocytes and myocytes. Hierarchical clustering
analysis using the same probe sets also enabled visualiza-
tion of the vicinity of efRNAi with tissues derived from the
mesenchymal lineage (Figure 1C; Figure S1). These in
silico analyses provided a first clue that EWS-FLI1 may
regulate a subset of genes involved in mesenchymal
commitment or differentiation.
We more precisely investigated similarities between
genes modulated by EWS-FLI1 in Ewing cell lines and
genes differentially expressed between MSCs and Ewing
tumors. SAM analyses enabled the identification of 3238
probe sets (2430 genes) differently expressed between
MSCs and ETs (absolute fold change > 2; q values <
102) (Table S2). Comparisons of MSCs/ETs gene sets
with the 289 genes identified between efRNAi and ctrlRNAi
using the same criteria demonstrated a very significant
overlap of 110 genes (p < 1016, exact binomial test) (Table
S2). Most of these genes behaved in a consistent manner
between both comparisons: genes downregulated by
EWS-FLI1 being overexpressed in MSCs as compared to
ETs and genes upregulated by EWS-FLI1 being underex-
pressed in MSCs (Figure 1D). We next investigated gene
sets specifically modulated by EWS-FLI1 in each individ-
ual cell lines. As expected, for each cell line, the overlap
between MSCs/ETs-differential genes and EWS-FLI1-
regulated genes was highly significant although it was
larger for A673. In addition to a common core set of genes
regulated by EWS-FLI1 in all three cell lines, this analysis
pointed out cell-line-specific gene sets (Figure 1E and Ta-
ble S2). Among genes common to the MSC/ET compari-
son and regulated byEWS-FLI1 in at least two of the Ewing
cell lines (gray area in Figure 1E), various signaling mole-
cules (DKK1, IGFBPs, CYR61) are key regulators of path-
ways controlling the commitment of MSCs to different lin-
eages (Kiepe et al., 2006; Schutze et al., 2005; van der
Horst et al., 2005). The overlap also contains numerous
genes whose products are involved in the cytoskeleton
and matrix remodeling associated with mesenchymal
cell biology (Table 1). In agreement with the proposed en-
dothelial potential of MSCs, some genes modulated by
EWS-FLI1 and expressed by MSCs have a critical role in
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Mesenchymal Origin of Ewing SarcomaFigure 1. EWS-FLI1-Silenced Ewing Cell
Profiles Converge toward a Mesenchy-
mal Stem Cell Expression Pattern
(A) Principal component analysis comparing
the gene expression profiles of EWS-FLI1-si-
lenced (efRNAi) and control (ctrlRNAi) A673,
EW24, and SK-N-MC Ewing cell lines, Ewing
tumors (ET), mesenchymal stem cells (MSC),
and various tissues using the whole transcrip-
tome data. Mesench, differentiated mesenchy-
mal tissues (smooth muscle, adipocytes);
Hemato, hematopoietic tissues; Epith, epithe-
lial tissues. The precise description of these
tissues is provided in Table S1. Each plotted
data point represents a single profile. In partic-
ular, individual data points for inhibition of
EWS-FLI1 by RNA interference are shown.
(B) Same analysis as in (A) but performed with
EWS-FLI1-modulated probe sets (SAM analy-
ses between efRNAi and ctrlRNAi samples,
absolute fold change > 3; q value < 0.01). The
two first components account for 41.8% of
the variation.
(C) Hierarchical clustering analysis (average
linkage method, 1  rank correlation distance
metric) using EWS-FLI1-modulated probe
sets. efRNAi samples cluster with mesenchy-
mal tissues and stem cells. The complete an-
notated cluster is provided as Figure S1.
(D) A significant proportion of genes differen-
tially expressed between efRNAi and ctrlRNAi
also distinguishes MSCs from ET. The blue
circle schematizes the set of genes exhibiting
significant variation (>2-fold; q value < 0.01)
between EWS-FLI1-silenced or -expressing
Ewing cells (efRNAi/ctrlRNAi), and the red
circle represents the set of genes differentially
expressed between MSCs and ETs (the
complete list of genes is provided in Table S2). The table represents the distribution of the 110 genes found in the overlap. Ninety-nine genes behave
consistently between MSC/ET and ef/ctrlRNAi: 44 genes upregulated in MSCs as compared to ETs are downregulated by EWS-FLI1 and 55 genes
downregulated in MSCs as compared to ETs are upregulated by EWS-FLI1.
(E) Venn diagram showing, among the 2540 genes which discriminates MSCs and ETs, the number of genes regulated by EWS-FLI1 in a cell-line-
specific manner. For each cell line, the number of EWS-FLI1-modulated genes (Welch test p value < 0.01, absolute fold change > 2) common
with the gene set of the MSC/ET comparison is represented. Among the 782, 364, and 382 genes regulated by EWS-FLI1 in A673, EW24, or
SK-N-MC, 320, 93, and 82 are common with the MSC/ET comparison, respectively.angiogenesis (Table 1). Finally, the inhibition of EWS-FLI1
also induced the expression of some master genes of the
mesenchymal differentiation (including SOX9 and BMP1)
that are not expressed in undifferentiated MSCs. To-
gether, these results strongly suggested that the EWS-
FLI1-silenced Ewing cells recover an expression pattern
related to that of MSCs. They also showed that a number
of neural genes expressed in ETs, but not in MSCs, are
regulated by EWS-FLI1 (Table 1).
EWS-FLI1-Silenced Ewing Cells Harbor
Mesenchymal Features
From these in silico analyses, we postulated that terminal
differentiation in the mesenchymal lineages might be
achieved upon combined effects of EWS-FLI1 silencing
and treatment of cells with appropriate differentiation
cocktails. To test this hypothesis, EWS-FLI1-silenced
EW24, SK-N-MC, and A673 cells were used to conduct
in vitro adipogenic differentiation experiments (Figure 2).Upon differentiation conditions, EW24 infected with the
control lentivirus, and hence harboring a normal EWS-
FLI1 expression, exhibited a mild induction of PPARg2
and FABP4 and a strong induction of LPL, three specific
markers of the adipocyte lineage (Figure 2A). The silencing
of EWS-FLI1 in EW24 cells grown in standard or differenti-
ation media led to a much stronger induction ofFABP4 and
to a lesser extent of PPARg2. Oil red O staining, which la-
bels lipidic vesicles, was not significant for EW24 infected
with the control virus either in basal or differentiation con-
ditions. The inhibition of EWS-FLI1 by itself induced a light
oil red O staining of a few cells (Figure 3B). However, this
staining was much more obvious when EWS-FLI1-si-
lenced cells were incubated in the presence of differentia-
tion medium (Figure 2B). These results indicated that
EW24 cells exhibit some degree of adipogenic conversion
upon incubation with specific cocktail or upon EWS-FLI1
silencing but that this commitment is much more pro-
nounced when both conditions are combined. A similarCancer Cell 11, 421–429, May 2007 ª2007 Elsevier Inc. 423
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below). In contrast, neither induction of markers nor oil red
O staining was observed in the SK-N-MC cell line.
Table 1. Main Genes Modulated by EWS-FLI-1 and
Differentially Expressed between MSC and ET
Symbol ET/MSC A673a SKNMC a EW24 a
Mesenchymal differentiation
CALD1 13.8 3.5 3.4 3.2
CYR61 21.3 6.0 10.7 11.6
DKK1 2.2 33.7 11.5 24.3
IGFBP5 7.0 25.8 8.7 8.5
IGFBP7 3.8 29.8 17.9 18.9
PPP1R1A 152.9 12.9 4.8
PRKCB1 236.4 17.4 3.1 2.7
PTGER3 23.2 2.8 4.1 2.7
SPARC 3.1 3.3 4.2 4.9
TPM1 8.2 13.7 5.8 5.8
VDAC1 10.2 11.7 8.8
Neurogenesis
ATP2B1 5.4 2.2 5.2
JARID2 4.5 2.4 2.9
NKX2-2 341.0 29.8 2.7
NLGN4X 29.3 2.2 2.9
OLFM1 39.3 5.6 2.5 2.4
PRNP 2.4 5.8 2.0
RCOR1 8.9 6.6 5.0
Extracellular matrix and cytoskeleton
ARHGAP29 22.1 4.9 2.8 5.2
ITGB5 10.9 2.7 2.9
MARCKS 4.1 2.2 2.2
MID1 29.7 2.0 2.6
PALLD 11.3 2.4 2.7 3.4
PLAT 26.5 11.1 2.1
RND3 91.5 23.2 4.6 8.7
S100A10 5.3 5.6 4.7 4.2
SDC2 29.1 2.0 5.2 5.6
SPTBN1 7.9 2.3 2.5
VCL 4.9 2.5 2.7 3.9
Angiogenesis
ADM 108.1 23.1 37.1 47.9
CYR61 21.3 6.0 10.7 11.6
TFPI 20.1 6.1 3.1 2.3
TNFRSF12A 3.9 2.2 3.6 2.9
a Mean fold change between ctrlRNAi and efRNAi samples.
 indicates EWS/FLI-1-repressed genes.424 Cancer Cell 11, 421–429, May 2007 ª2007 Elsevier Inc.In addition to adipogenic differentiation, MSC can also
commit to the osteogenic or chondrogenic lineages.
However, these differentiations necessitate up to several
weeks of incubation with specific media, which is hardly
compatible with the si- or shRNA approaches used in
the previous experiments. Indeed, due to a progressive
overgrowth of poorly inhibited cells, a long term and sta-
ble EWS-FLI1 silencing could not be achieved with these
systems. To circumvent this technical constrain, we con-
structed Ewing cell lines expressing a doxycycline (DOX)-
inducible shRNA-targeting EWS-FLI1. Two independent
clones (shA673-1C and -2C) were isolated. As shown in
Figure 3A, the induction of the shRNA led to a dramatic
reduction of EWS-FLI1 transcript and protein levels ob-
served by 24 h after addition of DOX in the culture me-
dium and remaining stable over time. In agreement with
previous observations based on siRNAs (Chansky et al.,
2004; Prieur et al., 2004), inducible EWS-FLI1 silencing
resulted in a considerable decrease of cell proliferation
associated with a reduced number of cells in the S phase
of the cell cycle and a simultaneous increase of the
amount of G1-phase cells (Figure S2). We first confirmed
that adipogenic differentiation conducted with both in-
ducible clones led to results similar to those described
above. In the presence of EWS-FLI1 (DOX), differentia-
tion medium led to a significant induction of the three
adipogenic markers (Figure 3B). The knockdown of EWS-
FLI1 in standard medium also led to an induction of these
transcripts. Nevertheless, the increased expression of
these three genes was higher when differentiation was
conducted in the presence of DOX, suggesting that
inhibition of EWS-FLI1 and differentiation cocktail may
provide additive or even synergistic effects (see PPARg2
and LPL). Finally, oil red O staining was positive only for
cells treated by both DOX and the differentiation cock-
tail (Figure 3C). Altogether, these data show that EWS-
FLI1-inhibited Ewing cells can accumulate lipid vesicles
and express adipogenic markers, two features highly
suggestive of a differentiation along the adipocyte
lineage.
Similar experiments were conducted for osteogenic dif-
ferentiation using quantitative RT-PCR analyses of three
markers specific for this lineage (SPP1, ALPL, and
RUNX2) and Von-Kossa staining. The EWS-FLI1 silencing
and subsequent growth arrest observed with DOX treat-
ment of shA673 cells were stable over time and long-
term differentiation experiments could thus be conducted.
The three aforementioned osteogenic markers were
induced by DOX and/or differentiation mix with different
patterns. The induction of ALPL was clearly dependent
upon the medium but not influenced by EWS-FLI1 (Fig-
ure 3D). Contrarily, differentiation medium and DOX
exhibited additive or even synergistic effects for RUNX2
andSPP1 inductions. Even more strikingly, the Von-Kossa
staining of shA673 grown for 3 weeks in differentiation me-
dium and DOX demonstrated the presence of a calcified
matrix, whereas this was observed neither in cells grown
in differentiation medium without DOX nor in standard
medium with or without DOX (Figure 3E). Together, these
Cancer Cell
Mesenchymal Origin of Ewing SarcomaFigure 2. Differentiation of EWS-FLI1-Silenced EW24 Cells along the Adipogenic Lineage
(A) Quantitative RT-PCR analysis of specific adipocyte markers on EW24 cells infected by theEWS-FLI1-specific (shEF1) or control (shCT) lentiviruses
grown in either standard () or differentiation medium (Diff). The mean values and standard deviation obtained for duplicate experiments are indicated.
(B) Oil red O staining of EW24 cells infected with shCT- or shEF1-encoding lentiviruses and cultured in standard () or adipogenic conditions (Diff).results show that EWS-FLI1-silenced Ewing cells can
exhibit characteristic features of osteocytes.
As MSCs are also precursors of chondrocytes, we
tested whether shA673 cells could differentiate along this
lineage. Pellet cultures of shA673 cells were performed
either in presence or absence of DOX and chondrogenic
differentiation medium. Whereas EWS-FLI1-expressing
shA673 cells remained flat and rapidly died, EWS-FLI1-
silenced shA673 formed a round pellet but ultimately died
prior to the delay necessary to evaluate terminal chondro-
cyte differentiation. However, quantitative RT-PCR exper-
iments showed that, in addition to the aforementioned
RUNX2 induction, COL10A1 and SOX9, two markers of
the chondrocyte lineage, were upregulated upon EWS-
FLI1 silencing (Figure 3D). These results suggested that
Ewing cells can engage the initial steps of chondrocyte
differentiation but cannot fully complete this process.
Finally, since MSCs can be characterized by the expres-
sion of several surface antigens (Covas et al., 2005; Izad-
panah et al., 2005; Oswald et al., 2004; Pittenger et al.,
1999), we investigated the expression of 10 surface
markers using FACS analyses in the presence or absence
of EWS-FLI1 (Figure 3F). Five of these (CD44, CD59,
CD73, CD29, and CD54) were expressed on shA673 cells
and induced by EWS-FLI1 inhibition. Three (CD90,
CD105, and CD166) were expressed but not modified by
EWS-FLI1 modulation. Finally, CD45 and CD31, two
markers expressed in hematopoietic stem cells or endo-
thelial cells but not in mesenchymal stem cells, were not
detected at the surface of Ewing cells whatever the
EWS-FLI1 status. Altogether, these results strengthen
the hypothesis of EWS-FLI1-silenced Ewing cells sharing
phenotypic characteristics with MSCs.
DISCUSSION
The fusion between EWS and members of the ETS family,
usually FLI1, is a critical event of Ewing sarcoma develop-ment. EWS-ETS fusions are only observed in tumors of the
Ewing family, suggesting that transformation is dependent
upon the specific action of this oncogene within a precise
cell background. Consequently, a thorough phenotypic
analysis of EWS-FLI1-silenced Ewing cells should give
insights into this cellular context. We have addressed
this issue investigating the transcription profile of EWS-
FLI1-silenced Ewing cells. Numerous genes involved in
neural development and differentiation are expressed in
ET and repressed upon inhibition of EWS-FLI1. This ob-
servation is in complete agreement with the occasional
presence of neural markers in ETs and with the recently re-
ported shift from myogenic to neural phenotype induced
by EWS-FLI1 expression in rhabdomyosarcoma cells
(Hu-Lieskovan et al., 2005). It confirms that EWS-FLI1 by
itself can promote the induction of some neural crest
genes. However, our data show that the neural profile of
Ewing cells is not sufficient for ETs to cluster among neural
tissues (Figure 1A).
The more striking in silico observation is that three
different EWS-FLI1-inhibited Ewing cell lines cluster
with MSCs when the analysis is performed with
EWS-FLI1-modulated genes. MSCs were initially de-
scribed by Friedenstein (Friedenstein et al., 1976), who
isolated plastic adherent cells from bone marrow capable
of differentiating into adipocytes, chondrocytes, and oste-
ocytes. More recently, a number of investigators have
shown that multipotent MSCs can be isolated from a vari-
ety of sources including bone marrow, adipose tissue,
connective tissues, placenta, and umbilical cord blood
(for review see Dennis and Charbord, 2002; Gregory
et al., 2005). In addition to the aforementioned lineages,
MSCs can also give rise to stromal cells supporting hema-
topoiesis and also probably to endothelial and vascular
smooth muscle cells. Our study shows that markers cur-
rently used for the isolation of MSCs may be induced
upon EWS-FLI1 inhibition (CD44, CD54, CD59, and
CD73). The in silico analysis described above is stronglyCancer Cell 11, 421–429, May 2007 ª2007 Elsevier Inc. 425
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Mesenchymal Origin of Ewing SarcomaFigure 3. Long-Term Silencing of EWS-
FLI1 Induces Mesenchymal Features
(A) Temporal analysis of EWS-FLI1 mRNA (left
panel) and protein (right panel) expression
upon doxycycline treatment of shA673 cells.
b-actin is used as a control. For mRNA expres-
sion, the mean values ± SD obtained for dupli-
cate experiments are indicated.
(B) Quantitative RT-PCR analysis of the spe-
cific adipocyte markers on shA673 induced
(+DOX) or not (DOX) by 1 mg/ml of doxycyclin
in either standard () or differentiation medium
(Diff). The mean values ± SD obtained for dupli-
cate experiments on both shA673 clones are
indicated.
(C) Oil red O staining of shA673-1C cultured in
standard () or adipogenic conditions (diff) in
the absence or presence of DOX.
(D) Quantitative RT-PCR analysis of specific
osteocyte and chondrocyte markers. The
mean values ±SD obtained for duplicate exper-
iments on both shA673 clones are indicated.
(E) Von-Kossa staining of the mineralized ma-
trix for shA673-1C cultured in standard () or
osteogenic differentiation (diff) conditions in
the presence or absence of DOX.
(F) FACS analyses of four cell surface markers
(CD59, CD73, CD54, and CD44). Cells were
treated (black lines) or not (gray lines) with
DOX during 6 days prior to FACS analyses.
Dashed lines represent control IgE.supported by experiments showing that EWS-FLI1-in-
hibited Ewing cells, but not parental Ewing cells, exhibit
differentiation characteristics of mesenchymal lineages.
Indeed, two out of three Ewing cell lines can be clearly
differentiated along the adipogenic lineage. This indicates
that, at least in these two cell lines, the apparatus respon-
sible for the adipogenic differentiation is present but im-
paired by EWS-FLI1. Long-term inhibition of EWS-FLI1
also shows that terminal osteogenic differentiation can
be observed with synthesis of a calcified matrix. These
experimental data are fully consistent with the previous
description of osteoid matrix in a subgroup of EWS-FLI1-
positive tumors called small-cell osteosarcoma (Oshima
et al., 2004). A less evident commitment of EWS-FLI1-si-
lenced cells toward the chondrogenic lineage is also ob-
served. Despite the death of Ewing cells observed upon
chondrocyte differentiation conditions impairing the evalu-
ation of the terminal differentiation, COL10A1, SOX9, and
RUNX2, three markers suggestive of a commitment to-426 Cancer Cell 11, 421–429, May 2007 ª2007 Elsevier Inc.ward the chondrocyte lineage, are induced upon EWS-
FLI1 silencing. SOX9 can be induced in chondrogenic
but also in neural differentiation. To further investigate
the hypothesis ofSOX9 induction being related to differen-
tiation along the neural lineage, we also analyzed the
expression of SNAI2, FOXD3, and PAX7, three markers
which are required for neural crest cell differentiation
(Basch et al., 2006). PAX7 was strongly (103) inhibited
by EWS-FLI1 silencing. FOXD3 and SNAI2 were slightly
inhibited or induced, respectively. Interestingly, none of
these markers were induced upon treatment of Ewing cells
with DMSO/HBA or DMSO/RA, two protocols previously
described for neural differentiation (Scintu et al., 2006;
Woodbury et al., 2002; Woodbury et al., 2000). These re-
sults strongly suggest that the SOX9 induction is related
to a chondrocyte rather than a neural commitment.
Altogether, these in silico and experimental data
strongly suggest that Ewing cells arise from MSC which
terminal mesenchymal differentiation is blocked by
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Mesenchymal Origin of Ewing SarcomaEWS-FLI1. It also shows that the phenotype of Ewing cells
is perverted from the mesenchymal-to-neural lineage by
EWS-FLI1. However, some Ewing cell lines (SK-N-MC),
despite a strong convergence toward a MSC gene ex-
pression profile upon EWS-FLI1 silencing, do not differen-
tiate, at least along the adipogenic lineage. This indicates
that the Ewing cell background, although related to MSC,
harbor cell-line-specific differences which may reflect di-
verse mesenchymal potentials of the original progenitors
in which the EWS-FLI1 fusion occurred. Alternatively,
some Ewing cell lines may have acquired secondary ge-
netic changes impairing differentiation processes.
The MSCs compartment consists of heterogeneous
population of cells, and presently, no single marker can
be used to isolate subpopulations of MSCs committed
to specific lineages. Stem cells with an extended differen-
tiation potential, in particular in the angiogenic lineage,
can be isolated from adipose tissue and bone marrow.
In that respect, it is striking that different genes involved
in angiogenesis are modulated by EWS-FLI1. The hypoth-
esis of a vascular differentiation potential of ET cells,
which was proposed by James Ewing himself, is further
supported by recent microarray data and by the observa-
tion of vascular mimicry in ET associated with the ability of
some Ewing cell lines to form vascular-like tubes in vitro
(Staege et al., 2004; van der Schaft et al., 2005). In that re-
spect, it is interesting to mention that FLI1, the wild-type
counterpart of EWS-FLI1, is a key regulator of early blood
vessel formation (Brown et al., 2000). Taken together, in
silico and experimental results suggest that ETs are de-
rived from MSCs that may have both mesenchymal and
vascular potentials. ET may therefore constitute an appro-
priate model to further study the characteristics of a com-
mon mesenchymal and vascular progenitor.
The identification of the Ewing primary cell constitutes
a key step toward a better understanding of ET biology.
The MSC origin may account for the predominant localiza-
tion of ET in bones or soft tissues, two major sources for
these stem cells. Through a precise spatiotemporal tar-
geting of EWS-FLI1 expression in the mouse, it should fos-
ter the development of a Ewing tumor model, which is
presently lacking and may be of considerable help to
achieve comprehensive insights into tumor initiation and
progression processes.
EXPERIMENTAL PROCEDURES
Inhibition of EWS-FLI1
A673 and SK-N-MC were obtained from ATCC. EW24 derived from
a bone tumor was kindly provided by Pr Gilbert Lenoir (Zucman et al.,
1993). All three cell lines exhibit a type 1 fusion transcript. For siRNA-
mediated silencing, A673 Ewing cells were transfected mainly as pre-
viously described (Prieur et al., 2004), except that transfection medium
was removed 6 hr after transfection instead of 24 hr and replaced by
fresh medium changed every 2 days. For doxycycline-inducible silenc-
ing, the oligonucleotides of the EWS-FLI1 short hairpin RNAs (shEF-1)
50-GATCCCGGCAGCAGAACCCTTCTTATTCAAGAGATAAGAAGGG
TTCTGCTGCCTTTTTGGAAA-30 (sense) and 50-AGCTTTTCCAAAAA
GGCAGCAGAACCCTTCTTATCTCTTGAATAAGAAGGGTTCTGCTGC
CGG-30 (antisense) were annealed and then cloned between the BglII
and HindIII restriction sites of the pTER vector (van de Wetering et al.,2003). Expression plasmids were transfected in A673 Ewing cell line
with the effectene transfection reagent (Qiagen, Paris, France) accord-
ing to the manufacturer’s instructions. A Tet repressor-expressing
clone (A673tetR5BIII) was selected on Blasticidine (20 mg/ml) and
then transfected with the pTER/shEF-1 construct encoding Zeocin re-
sistance (200 mg/ml). Two clones (shA673-1C and -2C), exhibiting
strong inhibition of EWS-FLI1 upon treatment with 1 mg/ml DOX, were
selected. For lentivirus-mediated silencing of EW24 and SK-N-MC cell
lines, the H1 promoter-tetO-shEF-1 cassette from pTER/shEF-1 vector
was inserted in the pTRIP lentiviral expression vector. Packaging and
titration using GFP as a reporter were performed according to the tro-
nolab website (http://tronolab.epfl.ch/).
Isolation of BMSCs
Human primary BMSCs were obtained after informed consent from
bone marrow aspirates (iliac crest) of patients undergoing hip replace-
ment surgery. Mononuclear cells were plated at the density of 50,000
cells/cm2 and cultured in a-MEM without nucleotides (Gibco BRL,
Invitrogen, Cergy-Pontoise, France), supplemented with 10% FCS
(Hyclone), L-glutamine 2 mM (Gibco BRL), and 1 ng/ml bFGF (AbCys).
After 2 weeks, confluent cells were detached with trypsin/EDTA and
replated at 1000 cells/cm2 (passage 1, P1). Cells were phenotyped
as BMSCs by flow cytometry (negative for CD34, CD31, and CD45
and positive for CD73, CD90, CD105, and CD44). The three-lineages
(adipocyte, osteocyte, and chondrocyte) differentiation potential of
these cells was controlled.
Isolation of RNAs and Microarray Analyses
Total RNAs were isolated using the Trizol Reagent (Invitrogen). RNAs
were isolated 9 days following transfection of A673 Ewing cells with
the specific EWS-FLI1 siRNA (siEF1) or with the control siRNA (siCT)
and 3 days after infection of EW24 and SK-N-MC with lentiviruses
encoding EWS-FLI1-specific or control shRNA. RNAs from 27 ET sam-
ples and from freshly isolated (P1) BMSCs were also used for micro-
array analyses. Experimental procedures for GeneChip microarray
were performed according to the Affymetrix GeneChip Expression
Analysis Technical Manual (Affymetrix, Santa Clara, CA) using HG-
U133A arrays. CEL files from E-AFMX-5 (Su et al., 2004) and from
E-MEXP-167 and E-MEXP-168 (Boquest et al., 2005) data sets were
downloaded from the EBI’s ArrayExpress repository (Parkinson et al.,
2005). Additional CEL files for EWS-FLI1-silenced A673 cells were
kindly provided by Steve Lessnick (Smith et al., 2006). All micro-
array data were simultaneously normalized using the gcrma package
version 1.1.4 in the R environment (R Development Core Team,
2006). Principal component analyses were performed using the PCA
tool of MeV TM4 software (Saeed et al., 2003). SAM analyses were
performed with the samr package version 1.22 (Tusher et al., 2001).
Microarray data are available at Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo/) public database with the accession
number GSE7007.
Real-Time Quantitative Reverse Transcription-PCR
cDNAs were synthesized from 1 mg of RNA using the GeneAmp RNA
PCR core Kit (Applied Biosystem, Courtaboeuf, France). Quantitative
PCR analyses were performed using TaqMan Assays-on-demand
Gene expression reagents (Applied Biosystem) with qPCR Mastermix
Plus without UNG (Eurogentec, Belgium). Reactions were run on an
ABI/PRISM 7500 (Applied Biosystem) and analyzed using the 7500
system SDS software. The following Assays-on-demand were used:
FABP4 (Hs00609791_m1), LPL (Hs00173425_m1), PPARG
(Hs00234592_m1), ALPL (Hs00758162_m1), RUNX2 (Hs00231692_m1),
SPP1 (Hs00167093_m1), SOX9 (Hs00165814_m1), COL10A1
(Hs00166657_m1), PAX7 (Hs00242962_m1), FOXD3 (Hs00255287_m1),
SNAI2 (Hs00161904_m1), and RPLP0 (Hs99999902_m1). RPLP0 ex-
pression, which does not vary upon shRNA induction or differentiation
conditions, was used for normalization. EWS-FLI1 expression was
quantified by SYBR green (Applied Biosystem) using the followingCancer Cell 11, 421–429, May 2007 ª2007 Elsevier Inc. 427
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GCCAAGCTCCAAGTCAATATAGC-30.
Cell-Cycle Analyses by Flow Cytometry
Cell-cycle analyses were performed by BrdU incorporation as previ-
ously described (Dauphinot et al., 2001). Samples were subjected to
FACS analysis (FACScalibur, BD Biosciences, San Diego, USA) and
the data were processed using CELL Quest software (BD Biosci-
ences). For cell surface markers detection, 105 cells were incubated
30 min at 4C in 100 ml of PBS with phycoerythrin (PE)-conjugated
mAb. Cells were then washed twice and proceeded immediately to
FACS analysis. The PE-conjugated antibodies from BD Biosciences
used were IgG1-PE (MOPC-2), CD29-PE (MAR4), CD31-PE (WM59),
CD44-PE (G44-26), CD45-PE (HI30), CD54-PE (HA58), CD59-PE
(H19), CD90-PE (5E10), and CD166-PE (3A6). CD105-PE (SN6) was
from Invitrogen.
Differentiation Assays
For adipogenic differentiation, cells were plated and grown for 2 days
at 37C, 5% CO2 in DMEM or RPMI containing 10% FCS, 0.5 mM
IsoButylMethylXanthine (Sigma), 1mM dexamethasone (Sigma), and
10 mg/ml Insulin (Sigma). Medium was then replaced by DMEM or
RPMI, 10% FCS, with 10 mg/ml insulin and cells were grown for 6 ad-
ditional days with medium changes every 2 days, then collected for
quantitative-RT-PCR or fixed in 4% paraformaldehyde (Sigma) prior
to staining with 0.3% w/v Oil-Red-O (Sigma) in 60% isopropanol. For
osteogenic differentiation, cells were grown in DMEM, 10% serum,
0.1 mM dexamethasone, 0.15 mM L-ascorbic acid (Sigma), 2 mM
b-glycerophosphate (Sigma) and 1 mM NaH2PO4 for 21 days. Parafor-
maldehyde-fixed calcium depositions were stained by the Von-Kossa
protocol including incubation with 5% silver nitrate (Sigma) for 30 min,
extensive washing with PBS, exposition for 20 min to UV and incuba-
tion in 5% sodium thiosulfate for 5 min. For chondrogenic differentia-
tion, cells were grown in pellet as previously described (Johnstone
et al., 1998). Briefly, 4 3 105 cells centrifuged 5 min at 1200 rpm in a
15 ml polypropylene tube were grown in pellet in 500 ml of DMEM with-
out serum but containing 0.1 mM dexamethasone, 0.15 mM L-ascorbic
acid, 0.35 mM proline, 1 mM sodium pyruvate, 13 ITS (Roche, Meylan,
France), 10 ng/ml TGFb3 (R&D system, Lille, France), and 10 ng/ml
IGF1 (Abcys) for 21 days.
Supplemental Data
The Supplemental Data include two supplemental figures and two
supplemental tables and can be found with this article online at
http://www.cancercell.org/cgi/content/full/11/5/421/DC1/.
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